OSI-774-206, Open-label, Phase 2 Study of Single-agent Erlotinib for Patients with Pediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205
|Effective start/end date||1/1/11 → 12/31/12|
- OSI Pharmaceuticals, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.